0001477932-23-008957alid_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

 

December 4, 2023 (November 9, 2023)

 

Allied Corp.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada

 

0-27675

 

33-1227173

(State or Other Jurisdiction

of Incorporation)

 

(Commission File Number)

 

(IRS Employer

Identification No.)

 

1405 St. Paul St., Suite 201, Kelowna, BC Canada

 

V1Y 9N2

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant's Telephone Number, Including Area Code: (877) 255-4337

 

 

_____________________________________________________________

(Former Name or Former Address, if Changed Since Last Report) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

 

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On or about November 9, 2023 the Registrant’s wholly owned subsidiary Allied Colombia S.A.S. entered into a Term Sheet (“Term Sheet”) for Contract Manufacturing Services with a EU-GMP certified partner in Portugal that will enable Allied to be able to offer Colombia produced flower with the EU-GMP (good manufacturing practices) approved certifications. As this partner is located in Portugal this flower will be positioned to be offered in European countries, as well as Australia.

 

The foregoing description is qualified by the actual terms of the Term Sheet attached as an exhibit hereto.

 

Item 9.01 Financial Statements and Exhibits.

 

The following Exhibits are included herein:

 

Exhibit No.

 

Description

 

 

 

10.1

 

Term Sheet for Contract Manufacturing Services dated October 27, 2023 between Blossom Genetics Unipessoal Lda, Allied Corp. and and Allied Colombia S.A.S.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL Document)

 

 

2

 

 

SIGNATURES

 

            Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 Allied Corp.

(Registrant)

    
Dated: December 4, 2023  By:/s/ Calum Hughes

 

 

Chief Executive Officer 
    

 

 

3

 

0001477932-23-008957alid_ex101.htm

  EXHIBIT 10.1

 

Strictly Private & Confidential

 

 

TERM SHEET

 

FOR CONTRACT MANUFACTURING SERVICES BETWEEN

 

BLOSSOM AND ALLIED CORP

 

27 October 2023

 

1.

Parties

Allied Corp

Headquarters: 1405 St. Paul Street, #201, Kelowna, BC V1Y 2E4 Canada

Contacts: Michael Moses michael@allied.health

 

Or

 

Allied Colombia S.A.S

Headquarters: Carrera 49 # 54 73 Barrio Pan de Azucar, Bucaramanga, Colombia

Contacts: Benjamin Rocha benjamin@allied.health

 

(Both individually or jointly known as “Allied”) and

 

Blossom Genetics Unipessoal Lda (“BLOSSOM”)

Head Office Address: Av. Infante Dom Henrique 26, 1149-096 Lisboa VAT No: 515982555

 

Contacts:

Oskar Fletcher - CEO Phone: +447702086515

Email: ofletcher@blossomgentics.com

 

Naeem Dungarwalla - CFO Phone: +447906492333

E-mail: ndungarwalla@blossomgenetics.com

Web page: www.blossomgenetics.com

 

2.

Services

Blossom shall provide end to end service for processing GACP cannabis flower to EU-GMP complaint final product medical

cannabis, according to the current regulations in “Eudralex: Volume

 

 

EU - GMP Supply Chain Services

1 | 4

 

 

 

 

Strictly Private & Confidential

 

 

 

 

4 Medicinal Products for Human and Veterinary Use: Good Manufacturing Practice and the Annex 7: Manufacture of Herbal Medicinal Product”.

 

Blossom, EU-GMP certified and license manufacturer of medical cannabis, will provide the following services:

 

•           Processing: Transforming GACP cannabis into EU-GMP medical cannabis flower

 

·        Testing: Regulatory testing required for valid batch release under EU-GMP I & II

 

·        Packaging & Branding: White label services for EU-GMP final product release

 

·        Warehousing: Product Storage under EU-GMP standards to ensure shelf life

 

·        Batch Release: Batch release sign-off by qualified person in line with EU-GMP regulations

 

·        Logistics & Distribution: Providing global delivery services including all import & export filings

 

Details in the Annex A.

 

3.

Commercial

BLOSSOM shall use commercially reasonable efforts to perform the services and supply the product in quantities requested by ALLIED on the date requested.

 

ALLIED shall be solely responsible for its costs relating to distribution and promotion of the product.

 

4.

Supply Price &

Services fee

Please refer to Annex B

 

5.

Forecasts

Please refer to Annex C.

 

6.

Payment Terms

Deposit - ALLIED shall pay for the order cost, 10% (ten per cent) of total order in advance after order placement and respective written confirmation by BLOSSOM and after sending the corresponding proforma invoice.

 

Processing & Packaging - ALLIED shall pay for the order cost, 40% (fourty per cent) once the COA results are back and Allied gives Blossom the green light to begin manufacturing. Thea final 50% (fifty per cent) will be payable upon final COA received and Final Product manufacture.

 

Logistics - ALLIED shall pay for the order cost, 100% (one hundred per cent) upon confirmation of the order placement.

 

 

EU - GMP Supply Chain Services

2 | 4

 

 

 

 

Strictly Private & Confidential

 

 

7.

Intellectual Property

ALLIED shall be solely responsible for ensuring that Product and artworks or text in packaging materials not infringe any third party’s Intellectual Property Rights in the territory of destination. In case of any claims arise, ALLIED shall be fully responsible and indemnify BLOSSOM.

 

8.

Termination

Each party shall have the right to terminate upon material breach by, or bankruptcy of, the other party.

 

9.

Diligence

Both parties shall undertake their respective responsibilities under the agreement in a business-like way and according to recognised standards.

 

10.

Confidentiality

Standard Clauses. Care required in controlling public notification of deal in order to safeguard commercial path of the project. Neither party shall be permitted to issue any press releases or other public announcements without the prior consent of the other party, unless required by applicable law.

 

11.

Insurance

Each party shall carry general and Product liability insurance or as appropriate such as care, custody and control insurance coverage.

 

12.

Dispute Resolution

Resolve through dialogue, then referral to CEOs (or their designee). If not resolved, parties shall agree be settled in accordance with the Rules of the ICC International Court of Arbitration by one or more arbitrators appointed in accordance with such Rules.

 

13.

Governing Law and

Jurisdiction

Lisbon, Portugal

 

 

 

EU - GMP Supply Chain Services

3 | 4

 

 

 

 

Strictly Private & Confidential

 

 

IN WITNESS WHEREOF, the Parties have caused this Term Sheet to be executed by their respective duly authorized representatives.

 

BLOSSOM

ALLIED

 

 

 

/s/ Benjamin Rocha

10/31/2023

 

 

Signature:

Signature:

 

/s/ Oskar Fletcher

/s/ Calum Hughes

Oskar Fletcher, CEO

2023-10-26

Date:

Date:

                                           

 

EU - GMP Supply Chain Services

4 | 4

 

 

 

ILY: ti�z'�r